+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Kidney Transplant Rejection - Pipeline Review, H2 2019

  • ID: 4901353
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 171 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Alphamab Oncology
  • Gilead Sciences Inc
  • ITB-Med AB
  • Medeor Therapeutics Inc
  • Novartis AG
  • Rigel Pharmaceuticals Inc
  • MORE
Kidney Transplant Rejection - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2019, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 7, 10, 1, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alphamab Oncology
  • Gilead Sciences Inc
  • ITB-Med AB
  • Medeor Therapeutics Inc
  • Novartis AG
  • Rigel Pharmaceuticals Inc
  • MORE
Introduction
Report Coverage
Kidney Transplant Rejection - Overview
Kidney Transplant Rejection - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Kidney Transplant Rejection - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Kidney Transplant Rejection - Companies Involved in Therapeutics Development
Alphamab Oncology
Amgen Inc
Amyndas Pharmaceuticals LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Enceladus Pharmaceuticals BV
Gilead Sciences Inc
Hansa Biopharma AB
Helocyte Biosciences Inc
Hillhurst Biopharmaceuticals Inc
Idogen AB
ITB-Med AB
JN Biosciences LLC
Kiniksa Pharmaceuticals Corp
Kyowa Kirin Co Ltd
Mabtech Ltd
Medeor Therapeutics Inc
MyeloRx LLC
Nekonal Sarl
NextCell Pharma AB
Novartis AG
OSE Immunotherapeutics
Pharmapraxis
Pharmicell Co Ltd
Rigel Pharmaceuticals Inc
Sangamo Therapeutics Inc
St George Street Capital Ltd
Talaris Therapeutics Inc
TolerogenixX GmbH
TRACT Therapeutics Inc
Veloxis Pharmaceuticals AS
Viela Bio Inc
Kidney Transplant Rejection - Drug Profiles
Kidney Transplant Rejection - Dormant Projects
Kidney Transplant Rejection - Discontinued Products
Kidney Transplant Rejection - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Kidney Transplant Rejection, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Kidney Transplant Rejection - Pipeline by Alphamab Oncology, H2 2019
Kidney Transplant Rejection - Pipeline by Amgen Inc, H2 2019
Kidney Transplant Rejection - Pipeline by Amyndas Pharmaceuticals LLC, H2 2019
Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc, H2 2019
Kidney Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, H2 2019
Kidney Transplant Rejection - Pipeline by Enceladus Pharmaceuticals BV, H2 2019
Kidney Transplant Rejection - Pipeline by Gilead Sciences Inc, H2 2019
Kidney Transplant Rejection - Pipeline by Hansa Biopharma AB, H2 2019
Kidney Transplant Rejection - Pipeline by Helocyte Biosciences Inc, H2 2019
Kidney Transplant Rejection - Pipeline by Hillhurst Biopharmaceuticals Inc, H2 2019
Kidney Transplant Rejection - Pipeline by Idogen AB, H2 2019
Kidney Transplant Rejection - Pipeline by ITB-Med AB, H2 2019
Kidney Transplant Rejection - Pipeline by JN Biosciences LLC, H2 2019
Kidney Transplant Rejection - Pipeline by Kiniksa Pharmaceuticals Corp, H2 2019
Kidney Transplant Rejection - Pipeline by Kyowa Kirin Co Ltd, H2 2019
Kidney Transplant Rejection - Pipeline by Mabtech Ltd, H2 2019
Kidney Transplant Rejection - Pipeline by Medeor Therapeutics Inc, H2 2019
Kidney Transplant Rejection - Pipeline by MyeloRx LLC, H2 2019
Kidney Transplant Rejection - Pipeline by Nekonal Sarl, H2 2019
Kidney Transplant Rejection - Pipeline by NextCell Pharma AB, H2 2019
Kidney Transplant Rejection - Pipeline by Novartis AG, H2 2019
Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics, H2 2019
Kidney Transplant Rejection - Pipeline by Pharmapraxis, H2 2019
Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd, H2 2019
Kidney Transplant Rejection - Pipeline by Rigel Pharmaceuticals Inc, H2 2019
Kidney Transplant Rejection - Pipeline by Sangamo Therapeutics Inc, H2 2019
Kidney Transplant Rejection - Pipeline by St George Street Capital Ltd, H2 2019
Kidney Transplant Rejection - Pipeline by Talaris Therapeutics Inc, H2 2019
Kidney Transplant Rejection - Pipeline by TolerogenixX GmbH, H2 2019
Kidney Transplant Rejection - Pipeline by TRACT Therapeutics Inc, H2 2019
Kidney Transplant Rejection - Pipeline by Veloxis Pharmaceuticals AS, H2 2019
Kidney Transplant Rejection - Pipeline by Viela Bio Inc, H2 2019
Kidney Transplant Rejection - Dormant Projects, H2 2019
Kidney Transplant Rejection - Dormant Projects, H2 2019 (Contd..1), H2 2019
Kidney Transplant Rejection - Dormant Projects, H2 2019 (Contd..2), H2 2019
Kidney Transplant Rejection - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Kidney Transplant Rejection, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alphamab Oncology
  • Amgen Inc
  • Amyndas Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Enceladus Pharmaceuticals BV
  • Gilead Sciences Inc
  • Hansa Biopharma AB
  • Helocyte Biosciences Inc
  • Hillhurst Biopharmaceuticals Inc
  • Idogen AB
  • ITB-Med AB
  • JN Biosciences LLC
  • Kiniksa Pharmaceuticals Corp
  • Kyowa Kirin Co Ltd
  • Mabtech Ltd
  • Medeor Therapeutics Inc
  • MyeloRx LLC
  • Nekonal Sarl
  • NextCell Pharma AB
  • Novartis AG
  • OSE Immunotherapeutics
  • Pharmapraxis
  • Pharmicell Co Ltd
  • Rigel Pharmaceuticals Inc
  • Sangamo Therapeutics Inc
  • St George Street Capital Ltd
  • Talaris Therapeutics Inc
  • TolerogenixX GmbH
  • TRACT Therapeutics Inc
  • Veloxis Pharmaceuticals AS
  • Viela Bio Inc
Note: Product cover images may vary from those shown
Adroll
adroll